Hypoxia has been shown to increase SCD expression through SREBP-1 [74], and IDH1 mutation increases SCD expression through the oncometabolite D-2-hydroxyglutarate, mainly in low-grade glioma and secondary glioblastoma where these mutations are common [75,76]. Here, SREBF1 is linked to glioblastoma.